在阿尔茨海默氏病中识别和验证与PANoptosis相关的基因
Wenbin Zhou1, Han Lin2, Xiaoyun Huang2
1Department of Neurology, Central People's Hospital of Zhanjiang, Guangdong Medical University Zhan-jiang Central Hospital, Zhanjiang, China.
Journal of Alzheimer's disease : JAD
|November 27, 2025
概括
这项研究确定了五个关键的PANoptosis相关基因 (ADCYAP1,BCL6,CXCR4,SPP1,PGF) 对于阿尔茨海默病 (AD) 进展至关重要. 它还揭示了阿尔茨海默病的两个不同的免疫亚型,为疾病机制提供了新的见解.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 阿尔茨海默病 (AD) 是老年人痴呆的主要原因.
- 新出现的证据突出显示了PANoptosis在AD病变发生过程中的重要作用.
研究的目的:
- 用生物信息学和机器学习方法研究PANoptosis在阿尔茨海默病中的潜在作用.
- 为了识别和验证关键的PANoptosis相关基因和特征在AD免疫细胞透.
主要方法:
- 从GEO数据库下载了与AD相关的微阵列数据集,并从GeneCards下载了PANoptosis基因.
- 使用权重基因共同表达网络分析 (WGCNA) 和机器学习模型来识别枢纽基因.
- 利用ceRNA网络构建,ssGSEA用于免疫细胞透分析,以及共识集群 (CC) 用于亚型识别.
主要成果:
- 在AD中确定了五个核心PANoptosis相关的枢纽基因:ADCYAP1,BCL6,CXCR4,SPP1和PGF,在细胞模型中得到验证.
- 开发了一种AD的高性能风险预测模型,并建立了一个ceRNA网络.
- 揭示了AD免疫细胞透的显著变化,与已识别的枢纽基因相关.
- 根据免疫透水平提出了两个不同的AD亚型:高和低.
结论:
- 五个与PANoptosis相关的基因与阿尔茨海默病的病理进展有显著的关联.
- 这项研究提出了阿尔茨海默病的两种新型免疫透性亚型,为向治疗提供了潜在的潜力.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764


